Roche informed European patients that it will discontinue development of emugrobart after studies failed to show consistent improvements in muscle growth and motor function. The decision affects a program aimed at spinal muscular atrophy and followed internal analyses indicating variable efficacy. Roche communicated the halt directly to patient groups and emphasized the data‑driven nature of the decision, leaving open questions about implications for related muscle‑preserving strategies in ongoing obesity trials.